DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Biotechnology

Healthcare
$8.59 -0.17%

-$0.01 today

Market cap
$463.49M
Beta
1.00
P/E (TTM)
-8.8
EPS (TTM)
-$0.65
52W Low $3.48High $10.42

Volume 0.21M

Average 0.19M

DMAC Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

DiaMedica Therapeutics Inc.NASDAQ: DMAC

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How DMAC compares with its peers on the latest reported figures

  • DMAC's LTM Mar 2026 gross profit of $0 is the 4th highest of the 7 companies compared; the peer median is $5.02M.
DMAC Competitors Peer median
Gross Profit for DMAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$187.95M +39.8%-10.0%80.9%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$18.41M -89.0%—92.0%
BIOABioAge Labs, Inc.LTM Mar 2026$10.25M +606.6%—99.4%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 ———
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$211K ———
PROKProKidney Corp.LTM Mar 2026-$2M -752.0%—224.4%
DNLIDenali Therapeutics Inc.LTM Jun 2026-$2.2M ——61.0%
Peer median (excluding DMAC) $5.02M-24.6%-10.0%92.0%

Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development8.77M7.84M13.11M19.06M24.61M
Selling, General & Admin4.88M6.16M8.16M7.62M9.78M
Operating Expenses13.65M14M21.27M26.68M34.4M
Depreciation & Amortization24K25K30K39K43K
EBITDA(13.54M)(13.62M)(19.31M)(24.38M)(32.7M)
EBITDA Margin—————
Operating Income(13.65M)(14M)(21.27M)(26.68M)(34.4M)
Operating Margin—————
Interest Income0002.3M0
Interest Expense00000
Other Income / Expenses82K353K1.93M2.27M1.66M
Income Before Tax(13.56M)(13.65M)(19.34M)(24.41M)(32.74M)
Pre-Tax Margin—————
Income Tax Expense28K28K43K30K28K
Net Income(13.59M)(13.68M)(19.38M)(24.44M)(32.77M)
Net Margin—————
EPS (Basic)(0.65)(0.52)(0.60)(0.60)(0.70)
EPS (Diluted)(0.65)(0.52)(0.60)(0.60)(0.70)
Weighted Avg Shares20.77M26.44M32.57M40.4M46.98M
Weighted Avg Shares (Diluted)20.77M26.44M32.57M40.4M46.98M

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Intrinsic Alpha fair value

Locked

Current Price

$8.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.